viewSareum Holdings PLC

Sareum hails government funding initiative for new COVID-19 treatments as a “welcome source of funding”

Sareum is currently carrying out preclinical research to assess the potential of its candidate, SDC-1801, in Covid

Sareum Holdings PLC -

Sareum Holdings PLC (LON:SAR) has described as a “welcome source of funding” a new government-backed platform that will fast-track the development of potentially ground-breaking COVID-19 treatments.

Launched just days ago (Feb 13), the Department of Health and Social Care’s AGILE system will provide financial backing for phase I trials.

Sareum is currently carrying out preclinical research to assess the potential of its candidate, SDC-1801, on COVID-19.

The drug is a selective, small-molecule TYK2/JAK1 kinase inhibitor that has also been earmarked as a potential combatant of autoimmune diseases.

Sareum's COVID-19 programme will assess whether SDC-1801 is able to damp down the so-called cytokine storm that results from an over-active inflammatory response to the illness.

Researchers will also evaluate whether the treatment could potentially re-establish protection against bacterial pneumonia following SARS-CoV-2 infection.

The work, which began in December and should take six months, has UK government grant backing. Sareum said if its preclinical efforts are successful it may be eligible for AGILE funding.

The company’s chief scientific officer, Dr John Reader, said: "We are delighted that the UK government has created the AGILE clinical trial platform and has provided the funding needed to support this exciting and much-needed initiative, which may represent a potential route of future funding for the company.

“Despite the successful UK vaccination programme, we believe that there is still a clear need for new therapies to treat severe respiratory inflammation arising from viral infections such as COVID-19.

“Should the company's current work programme be successful, we will consider this new initiative as a potential source of funding contributing towards advancing SDC-1801 as a potential treatment for COVID-19 patients."

Quick facts: Sareum Holdings PLC

Price: 1.725 GBX

Market: AIM
Market Cap: £56.37 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...


Market Report: Washington riots and Trump Twitter suspension drag down FTSE...

The Market Report with Katie Pilbeam. FTSE 100 has lost a little momentum this morning after reaching its highest level since early March on Wednesday.  Facebook and Twitter have blocked Donald Trump from their platforms after supporters swarmed the Capitol building on Wednesday. The US...

on 7/1/21

2 min read